Testing HN2302 for lupus and systemic sclerosis safety
Part of Immune system & allergy, Skin clinical trials.
This early-stage trial tests whether HN2302, a new type of genetic medicine, is safe and helps patients with lupus or systemic sclerosis. Researchers want to see if it can reduce symptoms and improve organ function in people with these autoimmune conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–69 years old
- Diagnosed with lupus (SLE) for at least 6 months with specific blood test results, OR systemic sclerosis (SSc) with recent skin changes
- Normal or near-normal heart, liver, and kidney function
- No active infections like hepatitis B, hepatitis C, or HIV
- No history of organ or stem cell transplant
- Willing to use effective birth control for 12 months after the study drug infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
This trial tests a new treatment called SNC116 for people with severe lupus who haven't gotten better with standard medicines. It aims to reduce lupus activity by targeting certain immune cells.
This study tests a new drug called HBM7020 to see how safe it is and how your body processes it. The trial includes healthy volunteers and people with autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma to understand if the drug might help reduce disease activity.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.